Work

Therapeutic Cancer Vaccine Fulfills the Promise of Immunotherapy in Prostate Cancer

Year: 2010

Type: article

Abstract: Evaluation of: Kantoff PW, Higano CS, Shore ND et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010). For many years, preclinical and clinical studies have attempted to harness the power of the immune system and focus it on malignant cells in an attempt to improve clinical outcomes for patients with cancer. This paper describes the landmark Phase III trial that led to the first US FDA approval of a therapeutic cancer vaccine. In a randomized trial of 512 patients, those treated with sipuleucel-T survived for 25.8 months compared with those treated with placebo, who survived 21.7 months (HR: 0.78; p = 0.03). There was, however, no change in time to progression, which may relate to the underlying mechanism of this new class of therapeutics.

Source: Immunotherapy

DOI: 10.2217/imt.10.77

Authors: Ravi A Madan, James L Gulley

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Center for Cancer Research, National Institutes of Health, U.S. Food and Drug Administration, National Cancer Institute